Mucin 1 - Pipeline Review, H1 2018

  • ID: 4451696
  • Drug Pipelines
  • 86 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc
  • Bavarian Nordic A/S
  • Bioleaders Corp
  • Boehringer Ingelheim GmbH
  • Etubics Corp
  • GeoVax Labs Inc
  • MORE
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H1 2018

Summary

According to the recently published report 'Mucin 1 - Pipeline Review, H1 2018'; Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response.

The report 'Mucin 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Non Malignant Disorders which include indications Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Metastatic Breast Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenomas, Colorectal Cancer, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
  • The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc
  • Bavarian Nordic A/S
  • Bioleaders Corp
  • Boehringer Ingelheim GmbH
  • Etubics Corp
  • GeoVax Labs Inc
  • MORE
Introduction

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Overview

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Companies Involved in Therapeutics Development

Akshaya Bio Inc

Bavarian Nordic A/S

Bioleaders Corp

Boehringer Ingelheim GmbH

Etubics Corp

GeoVax Labs Inc

Merck KGaA

Minerva Biotechnologies Corp

Peptron Inc

Transgene SA

Vaxil Bio Therapeutics Ltd

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Drug Profiles

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLSM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target MUC1 for Gastric Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GO-203/NPs - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GO-2032c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImMucin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit MUC1 for Metastatic Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecemotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 1 to Target MUC-1 Protein for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 2 to Target MUC-1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 3 to Target MUC-1 Protein for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Mucin 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Dormant Products

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Discontinued Products

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Product Development Milestones

Featured News & Press Releases

Oct 30, 2017: Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC

Oct 12, 2017: Peer Reviewed Scientific Publications Highlight TG4010's Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors

Oct 09, 2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress

Sep 11, 2017: Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer

Aug 30, 2017: GeoVax Presents Preliminary Data for Cancer Vaccine

Jul 24, 2017: Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer

May 23, 2017: Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials

Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer

Mar 13, 2017: First Patient Dosed in Phase 2 Trial Evaluating Transgenes TG4010 in Combination With Opdivo (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer

Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer

Mar 03, 2017: Vaxil Announces Novel Immunotherapy Poster Presentation at 2017 American Association for Cancer Research Meeting

Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer

Dec 29, 2016: Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer

Dec 07, 2016: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nov 29, 2016: Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Indication, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products under Investigation by Universities/Institutes, H1

Products under Investigation by Universities/Institutes, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Pipeline by Akshaya Bio Inc, H1

Pipeline by Bavarian Nordic A/S, H1

Pipeline by Bioleaders Corp, H1

Pipeline by Boehringer Ingelheim GmbH, H1

Pipeline by Etubics Corp, H1

Pipeline by GeoVax Labs Inc, H1

Pipeline by Merck KGaA, H1

Pipeline by Minerva Biotechnologies Corp, H1

Pipeline by Peptron Inc, H1

Pipeline by Transgene SA, H1

Pipeline by Vaxil Bio Therapeutics Ltd, H1

Dormant Products, H1

Discontinued Products, H1

List of Figures

Number of Products under Development by Stage of Development, H1

Number of Products under Development by Therapy Areas, H1

Number of Products under Development by Top 10 Indications, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akshaya Bio Inc
  • Bavarian Nordic A/S
  • Bioleaders Corp
  • Boehringer Ingelheim GmbH
  • Etubics Corp
  • GeoVax Labs Inc
  • Merck KGaA
  • Minerva Biotechnologies Corp
  • Peptron Inc
  • Transgene SA
  • Vaxil Bio Therapeutics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll